Skbloom

Novartis

https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-moderate-severe-plaque-psoriasis

Novartis Cosentyx receives FDA approval for treatment of children ...

Jun 1, 2021 ... Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis ... This is the first ...

https://www.cosentyx.com/

COSENTYX® (secukinumab) | Home Page

people 6 years of age and older with moderate to severe plaque psoriasis (PsO) ... Novartis reserves the right to rescind, revoke, or amend this program ...

Novartis Philippines

https://www.novartis.com/ph-en/patient-resources/psoriasis

Psoriasis | Novartis Philippines

Psoriasis. Psoriasis is a chronic, non-communicable, painful, disfiguring and disabling disease for which there is no cure and with great negative impact on ...

https://www.uptodate.com/contents/chronic-plaque-psoriasis-in-adults-overview-of-management/contributor-disclosure

Contributor disclosures - UpToDate

... [Psoriasis]; Sensal Health [Psoriasis]. Grant/Research/Clinical Trial Support ... Novartis [Psoriasis]; Ortho Dermatologics [Psoriasis, acne]; Perfect ...

Novartis United States of America

https://www.novartis.com/us-en/news/media-releases/fda-approves-novartis-cosentyx-first-intravenous-iv-formulation-interleukin-17a-antagonist-rheumatic-diseases

FDA approves Novartis Cosentyx® as first intravenous (IV ...

Oct 6, 2023 ... First new intravenous (IV) treatment option in six years for adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and ...

https://ngcs.novartis.com/tpcinterest.jsp

AREAS OF THERAPEUTIC INTEREST

Psoriasis; Psoriatic Arthritis; Transplant; Vascular Inflammation in CVD. Novartis Oncology Office of Grants and Education (OGE) OGE will receive and review ...

Novartis

https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-eu-approval-first-line-systemic-treatment-pediatric-psoriasis

Novartis Cosentyx® receives EU approval for first-line systemic ...

Aug 3, 2020 ... ... psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS), over 100 studies and with more than 340,000 patients treated worldwide ...

https://pmc.ncbi.nlm.nih.gov/articles/PMC10460311/

Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled ...

Jun 21, 2023 ... NCT03668613 (Novartis Study Code CAIN457A2311, referred to as A2311), actual study start date: August 29, 2018; actual primary completion date: ...

Novartis

https://www.novartis.com/news/media-releases/novartis-announces-fda-approval-first-il-17a-antagonist-cosentyxtm-secukinumab-moderate-severe-plaque-psoriasis-patients

Novartis announces FDA approval for first IL-17A antagonist ...

Jan 21, 2015 ... Novartis announces FDA approval for first IL-17A antagonist Cosentyx(TM) (secukinumab) for moderate-to-severe plaque psoriasis patients.

BioSpace

https://www.biospace.com/novartis-wins-fda-approval-for-intravenous-formulation-of-cosentyx-in-rheumatic-diseases

Novartis Wins FDA Approval for Intravenous Cosentyx Formulation ...

Oct 9, 2023 ... This latest approval covers existing indications of Cosentyx, including ankylosing spondylitis (AS), psoriatic arthritis (PsA) and non- ...

Recommendation

Recommendation